益气活血中药复方影响病毒性心肌炎心肌细胞基因表达的实验研究
|
摘要
研究目的:病毒性心肌炎(Viral myocarditis,VMC)是临床上最常见的感染性心肌病,它是由嗜心性病毒感染所引起的心肌细胞变性、坏死和间质炎性细胞浸润以及纤维渗出等为主要改变的心肌疾病,可进一步并发严重的心律失常、心力衰竭、心源性休克甚至猝死,亦可演变为扩张型心肌病。导致病毒性心肌炎的病毒中,最为主要是柯萨奇B组病毒(CVB),在CVB的六个血清分型中,CVB3具有强嗜心性,所以,近来开展的各项研究主要是针对以CVB3感染所建立的病毒性心肌炎模型。因为VMC自身具有极高的危害性,所以本课题选择病毒性心肌炎作为研究的主要对象,由于小儿及成人的各个年龄段均可感染患病,急性期后,又有可能进一步演变为扩张型心肌病,并且VMC还可引起小范围的爆发流行,特别是近年来病毒性心肌炎的发病率更是呈现上升态势,所以,针对CVB_3病毒性心肌炎的治疗机制的研究更加显得尤为重要。
本研究是在中医脏腑理论学说及伤寒、温病学说等研究的基础上,结合多年的临床诊治经验,发现“气虚血瘀”是病毒性心肌炎发生的主要内在因素,并据此精心筛选出由黄芪、白参、郁金、丹参、麦冬等药组成的益气活血中药复方来治疗病毒性心肌炎,具有显著的抗心律失常和减轻心肌损伤等作用,但该中药复方的具体作用机制尚不明确。因此,本研究拟建立CVB3心肌细胞感染模型,利用改良的抑制性消减杂交(suppression subtractive hybridization ,SSH)等分子生物学技术,来探讨受CVB_3攻击的宿主细胞中与益气活血中药复方观察组中趋化因子CXCL12、Sash1、small inducible cytokine A2、ribosomal protein S4基因的表达变化,以期进一步从基因水平揭示益气活血中药复方调控VMC的作用靶标和途径信息,为深入研究该方在病毒性心肌炎治疗过程中所具有的生物学效应和意义提供新的理论基础和实验依据,从而进一步证实益气活血法是治疗病毒性心肌炎的有效方法,益气活血中药复方是治疗CVB_3病毒性心肌炎的有效方剂。
材料与方法:
1实验材料
1.1实验动物
新生2-3天wistar乳鼠(辽宁中医药大学实验动物中心负责提供)。
1.2实验药品及相关试剂
特级胎牛血清(灏洋生物,天津)、高糖DMEM(Gibco,美国)、硫酸链霉素(美罗大药厂,大连)、青霉素钠(华北制药股份有限公司,石家庄)、碳酸氢钠(天津市氨基酸公司,天津)、MTT(Sigma,美国)、胰蛋白酶(Invitrogen,美国)、DMSO(Sigma,美国)、PBS(博士德,武汉)等。ANT(santa,美国)、PFP(santa,美国)、α-MHC(abcam,美国)、DAB显色试剂盒(博士德,武汉)、SABC免疫组化(过氧化物酶)试剂盒(博士德,武汉)、Triton X-100(Solarbio,北京)、抗原修复液(博士德,武汉)。
2实验方法
2.1益气活血中药复方的细胞毒性测定:
把复苏的Hela细胞提取出来,然后经培养瓶传代,接种到96孔的细胞培养板中,每孔0.2ml,放置于37℃,5%二氧化碳培养箱中进行培养,当出现呈单层贴壁生长的Hela细胞时,测量益气活血中药复方的最大无毒剂量。将益气活血中药复方注射液用DMEM培养液从原液开始配制成11个浓度。每个浓度设置4个复孔,每孔0.2ml,另外设4个对照孔加入正常的生长液。观察细胞生长状态(分别于24h和48h),参考正常对照孔的细胞形态,最大无毒剂量(TD0)是以不引起细胞病变的最大药物稀释浓度。2.2 CVB_3病毒毒力滴定:
在96孔的培养板中制备单层生长的Hela细胞,弃掉生长液,并且各培养孔用HBSS液洗涤2次。将CVB_3病毒以10倍浓度从10-1用含2%胎牛血清的维持液稀释到10-8,接种于96孔的培养板中,每孔0.1ml,每个浓度设4个复孔,另外设4个正常孔对照,每孔加入0.1ml维持液,放置于37℃,5%二氧化碳培养箱中进行培养,观察细胞的病变情况(分别于24h和48h)。
2.3益气活血中药复方对CVB_3所致心肌细胞死亡的抑制实验(MTT法):
将50%组织感染量浓度的CVB_3病毒与提取后的对数生长期心肌细胞混合0.2ml/孔,吸附心肌细胞2h。在加入含有益气活血中药复方的生长液之前,需保证该生长液已被稀释8个浓度。核算方法以药物最大无毒剂量为标尺。4个复孔对应一个浓度,在剂量上,设置值为0.2ml/孔,每个浓度还设有1个调零孔。DMEM培养液需在四十八个小时之后才能添加,剂量为0.18ml/孔,一切就绪后,方可放入MTT溶液0.02ml。另外MTT溶液需要再在培养箱中一定时限,即4小时。吸弃孔内培养液,加入DMSO,每孔0.15ml,置于振荡器上,振荡8min,在酶联免疫检测仪490 nm处测量各孔的吸光值(OD)。
2.4益气活血中药复方对CVB_3病毒性心肌炎心肌细胞趋化因子CXCL12、SASH1、MCP-1、Rps4基因表达的影响:
利用改良的抑制性消减杂交技术(suppression subtractive hybridization,SSH),分离益气活血中药复方观察组和大鼠心肌细胞CVB_3感染组差异表达的基因,并通过荧光RT-PCR对上述结果进行验证。
3实验结果:
3.1CVB_3病毒毒力滴定:50%培养细胞CVB_3病毒感染量为1×10~(-4.5)。
3.2益气活血中药复方细胞毒性测定:益气活血中药复方的最大无毒浓度是7.813mg/ml。
3.3益气活血中药复方对CVB_3所导致的心肌细胞死亡的抑制实验(MTT法):CVB_3攻击后的心肌细胞被益气活血中药复方最大无毒剂量干预时,其吸亮度值也最大,和其他稀释度组相比,差异显著,(P<0.0010),从而可以证实益气活血中药复方的最大无毒剂量具有显著的抑制CVB_3所致心肌细胞死亡的作用。
3.4益气活血中药复方对CVB_3病毒性心肌炎心肌细胞趋化因子CXCL12、SASH1、MCP-1、Rps4基因表达的影响:改良的SSH结果显示益气活血中药复方观察组中趋化因子CXCL12、SASH1、MCP-1、Rps4基因的表达比CVB_3病毒组中高,这一结果通过荧光RT-PCR得到验证。
实验结论:
1.利用体外培养的方法,成功建立了被CVB_3攻击的新生乳鼠原代心肌细胞的感染模型。
2.通过观察益气活血中药复方对CVB_3病毒性心肌炎心肌细胞趋化因子CXCL12、SASH1、MCP-1、Rps4基因表达的影响,进一步证实了以益气活血药为主组成的中药复方,具有多靶点、多层面和多作用的效果。
3.本课题从更深层次论证了益气活血法对病毒性心肌炎疗效的确切性,而益气活血中药复方是诊治病毒性心肌炎的有效方剂,揭示本方在VMC的治疗中具有广阔的应用前景。
Objective:Viral myocarditis refers to infection caused by a variety of in order to myocardial cell degeneration and necrosis, interstitial inflammatory cell infiltration and fibrous exudation for cardiac disease, major changes occur. Its pathogenicity to Coxsackie virus group B virus (CVB) is the main, and in the six CVB serotypes in, CVB3 Anopheles strong mind, therefore, the current principal for the establishment of viral infection in CVB3 myocarditis model to carry out the research, the subject of viral myocarditis to choose research subjects as a main reason is that this disease has a high self-harm, such as children and adults of all ages can be involved stage disease, acute period, and into a dilated the possibility of cardiomyopathy at the same time, can also be caused by small-scale outbreaks, and viral myocarditis in recent years the incidence of the rise is, therefore, against CVB3 viral myocarditis treatment mechanism appears imminent.
With that in mind, this research will establish a CVB3 mycocarditis cell infection model, through certain molecular biological technologies like the improved suppression subtractive hybridization (SSH), in order to explore the genetic expressive change of the chemotatic factors such as CXCL12、Sash1、small inducible cytokine A2、ribosomal protein S4, which are located in the attacked host cell and in the treatment group that use the method of Chinese Herbal boosting qi and enlivening blood formula (YiQi HuoXue Chinese Herbal Compound). The objective is to release the regulating function and the mode of Chinese Herbal boosting qi and enlivening blood formula to VMC, so as to further explore its biological effect and significance in the treatment of VMC, and to provide new theoretical basis and experimental basis. The research will also go further in showing that boosting qi and enlivening blood is a proven formula for treatment of VMC.
Material and method:
1.Research Materials
1.1 Experimental Animals Newborn 2-3d wistar rats (provided by LiaoNing Chinese Medical College Department of Experimental Animals)
1.2 Experimental Medicine and Reagents High Glucose DMEM(Gibco , USA) , Specialize fetal bovine serum(HaoYang Biological, TianJin), Penicillin (North China Pharmaceutical Co., Ltd., Shijiazhuang), Streptomycin sulfate (Merro Pharma, Dalian),Sodium bicarbonate (Tianjin Amino Acid Company, Tianjin),MTT(Sigma, USA), DMSO(Sigma, USA), Trypsin(Invitrogen, USA), PBS(Boster, WuHan). PFP (Santa, USA), ANT (Santa, USA), a-MHC(Abcam, USA), SABC immunohistochemistry (peroxidase)Kit (Boster, Wuhan), Antigen retrieval solution (Boster, Wuhan), Chromogenic DAB kit (Boster, Wuhan), Triton X-100(Solarbio, Beijing).
2.Research Methods
2.1 Yiqihuoxue cytotoxicity determination of compound Chinese medicine :Recovery from Hela cells by passage culture bottles after inoculation with 0.2ml of each hole to 96 hole cell culture plate, the home 37℃, 5% carbon dioxide incubator to cultivate, when Hela cells were adherent monolayer growth, the measurement Yiqihuoxue largest non-toxic dose of Chinese medicine compound. DMEM culture medium with the traditional Chinese medicine compound Yiqihuoxue injection started from the stock solution concentration of the preparation 11. Each hole 0.2ml, each concentration for 4-hole complex, plus an additional four control normal growth and pore fluid. In 24h, 48h observation of cell growth state, a reference hole normal cells to the cytopathic effect is not caused by the largest concentration of drug dilution largest concentration of non-toxic (TD0).
2.2 CVB3 Virulence Titration: In the 96-well plate dispose of the mono-layer Hella cell growth and wash each well twice with the HBSS solution. Using 2%fetal bovine serum as suspension, add ten concentrations of CVB3 virus diluted from 10-1 to 10-8. Each well with 0.1ml. On the 96 well plate, each concentration will be placed into four wells and four additional wells as a control. Each solution will be kept at 0.1ml and placed into a 5% Carbon Dioxide incubator and kept at 37oC. Cellular pathology will be observed at 24h and 48h. observation cell lesions.
2.3 Yiqihuoxue Chinese herbal compound on CVB3-induced myocardial cell death inhibition (MTT method) :Logarithmic phase from myocardial cells, 0.2ml of each hole by adding half the volume of the concentration of tissue infections myocytes CVB3 virus adsorption 2h. Suction disposable culture medium containing the virus, containing 2% fetal bovine serum to the maintenance of gently washing liquid on it, adding the largest non-toxic drug dosage from the initial dilution of the concentration of 8 Yiqihuoxue Chinese herbal compound containing the growth solution, 0.2 per hole ml, each concentration for 4-hole complex, a separate zero-hole. In 48h, each hole by adding 0.18ml DMEM culture medium, then add 0.02ml MTT solution into incubator to continue to foster 4h, carefully suction hole disposable culture medium, each hole by adding 0.15ml DMSO, the oscillation oscillator home 8min, in enzyme-linked immunosorbent assay detector 490 nm of the hole measured absorbance (OD).
2.4 the influence of YiQi HuoXue Chinese Herbal Compound to the genetic expression of Viral myocarditis,(VMC) chemotatic factors such as CXCL12, Sash1, MCP-1, ribosomal protein S4: through the improved suppression subtractive hybridization (SSH), the rat cardiac muscle cell CVB3 infection group and the gene that has a differential expression in YiQi HuoXue Chinese Herbal Compound group will be demeshed. The result wil be proved through FL RT-PCR.
3 Experimental Results:
3.1 Determination of Boosting Qi and Enlivening Blood Formula cytotoxicity: the maximum non-toxic dose for the formula is 7.813mg/ml.
3.2 CVB3 virulence titration: the infection rate of 50% cultured CVB3 virus cells is 1×10~(-4.5).
3.3 Boosting qi and enlivening blood formula inhibition of myocardial cell death from CVB3 virus(MTT method):use of maximum non-toxic dose boosting qi and enlivening blood formula on post-attack myocardial cells, had the largest absorption value, and in comparison with other dilutions there was a clear difference, p<0.001. This shows that the maximum non-toxic dose of boosting qi and enlivening blood formula has a clear inhibitory effect on CVB3 induced myocardial cell death.
3.4the influence of YiQi HuoXue Chinese Herbal Compound to the genetic expression of Viral myocarditis,(VMC) chemotatic factors such as CXCL12, Sash1, MCP-1, ribosomal protein S4: The results of SSH showed that genetic expression of CXCL12, Sash1, MCP-1, ribosomal protein S4 in treatment group were higher than that in CVB3 infection group. The results of fluorescent RT-PCR agreed with that of SSH.
Conclusion:
1.To primary neonatal rat cardiac myocytes in vitro methods, the establishment of the myocardial cells attack CVB3 infection model.
2.Through observing the influence of YiQi HuoXue Chinese Herbal Compound to the genetic expression of Viral myocarditis,(VMC) chemotatic factors such as CXCL12, Sash1, MCP-1, ribosomal protein S4, the multi-functional, multistrata, multi-targeting effect of YiQi HuoXue Chinese Herbal Compound have been confirmed.
3.The experiments further confirmed Yiqihuoxue VMC is an effective treatment of the law, and medicine Yiqihuoxue VMC compound is an effective prescription treatment, suggesting that this treatment in the VMC has broad application prospects.
本研究是在中医脏腑理论学说及伤寒、温病学说等研究的基础上,结合多年的临床诊治经验,发现“气虚血瘀”是病毒性心肌炎发生的主要内在因素,并据此精心筛选出由黄芪、白参、郁金、丹参、麦冬等药组成的益气活血中药复方来治疗病毒性心肌炎,具有显著的抗心律失常和减轻心肌损伤等作用,但该中药复方的具体作用机制尚不明确。因此,本研究拟建立CVB3心肌细胞感染模型,利用改良的抑制性消减杂交(suppression subtractive hybridization ,SSH)等分子生物学技术,来探讨受CVB_3攻击的宿主细胞中与益气活血中药复方观察组中趋化因子CXCL12、Sash1、small inducible cytokine A2、ribosomal protein S4基因的表达变化,以期进一步从基因水平揭示益气活血中药复方调控VMC的作用靶标和途径信息,为深入研究该方在病毒性心肌炎治疗过程中所具有的生物学效应和意义提供新的理论基础和实验依据,从而进一步证实益气活血法是治疗病毒性心肌炎的有效方法,益气活血中药复方是治疗CVB_3病毒性心肌炎的有效方剂。
材料与方法:
1实验材料
1.1实验动物
新生2-3天wistar乳鼠(辽宁中医药大学实验动物中心负责提供)。
1.2实验药品及相关试剂
特级胎牛血清(灏洋生物,天津)、高糖DMEM(Gibco,美国)、硫酸链霉素(美罗大药厂,大连)、青霉素钠(华北制药股份有限公司,石家庄)、碳酸氢钠(天津市氨基酸公司,天津)、MTT(Sigma,美国)、胰蛋白酶(Invitrogen,美国)、DMSO(Sigma,美国)、PBS(博士德,武汉)等。ANT(santa,美国)、PFP(santa,美国)、α-MHC(abcam,美国)、DAB显色试剂盒(博士德,武汉)、SABC免疫组化(过氧化物酶)试剂盒(博士德,武汉)、Triton X-100(Solarbio,北京)、抗原修复液(博士德,武汉)。
2实验方法
2.1益气活血中药复方的细胞毒性测定:
把复苏的Hela细胞提取出来,然后经培养瓶传代,接种到96孔的细胞培养板中,每孔0.2ml,放置于37℃,5%二氧化碳培养箱中进行培养,当出现呈单层贴壁生长的Hela细胞时,测量益气活血中药复方的最大无毒剂量。将益气活血中药复方注射液用DMEM培养液从原液开始配制成11个浓度。每个浓度设置4个复孔,每孔0.2ml,另外设4个对照孔加入正常的生长液。观察细胞生长状态(分别于24h和48h),参考正常对照孔的细胞形态,最大无毒剂量(TD0)是以不引起细胞病变的最大药物稀释浓度。2.2 CVB_3病毒毒力滴定:
在96孔的培养板中制备单层生长的Hela细胞,弃掉生长液,并且各培养孔用HBSS液洗涤2次。将CVB_3病毒以10倍浓度从10-1用含2%胎牛血清的维持液稀释到10-8,接种于96孔的培养板中,每孔0.1ml,每个浓度设4个复孔,另外设4个正常孔对照,每孔加入0.1ml维持液,放置于37℃,5%二氧化碳培养箱中进行培养,观察细胞的病变情况(分别于24h和48h)。
2.3益气活血中药复方对CVB_3所致心肌细胞死亡的抑制实验(MTT法):
将50%组织感染量浓度的CVB_3病毒与提取后的对数生长期心肌细胞混合0.2ml/孔,吸附心肌细胞2h。在加入含有益气活血中药复方的生长液之前,需保证该生长液已被稀释8个浓度。核算方法以药物最大无毒剂量为标尺。4个复孔对应一个浓度,在剂量上,设置值为0.2ml/孔,每个浓度还设有1个调零孔。DMEM培养液需在四十八个小时之后才能添加,剂量为0.18ml/孔,一切就绪后,方可放入MTT溶液0.02ml。另外MTT溶液需要再在培养箱中一定时限,即4小时。吸弃孔内培养液,加入DMSO,每孔0.15ml,置于振荡器上,振荡8min,在酶联免疫检测仪490 nm处测量各孔的吸光值(OD)。
2.4益气活血中药复方对CVB_3病毒性心肌炎心肌细胞趋化因子CXCL12、SASH1、MCP-1、Rps4基因表达的影响:
利用改良的抑制性消减杂交技术(suppression subtractive hybridization,SSH),分离益气活血中药复方观察组和大鼠心肌细胞CVB_3感染组差异表达的基因,并通过荧光RT-PCR对上述结果进行验证。
3实验结果:
3.1CVB_3病毒毒力滴定:50%培养细胞CVB_3病毒感染量为1×10~(-4.5)。
3.2益气活血中药复方细胞毒性测定:益气活血中药复方的最大无毒浓度是7.813mg/ml。
3.3益气活血中药复方对CVB_3所导致的心肌细胞死亡的抑制实验(MTT法):CVB_3攻击后的心肌细胞被益气活血中药复方最大无毒剂量干预时,其吸亮度值也最大,和其他稀释度组相比,差异显著,(P<0.0010),从而可以证实益气活血中药复方的最大无毒剂量具有显著的抑制CVB_3所致心肌细胞死亡的作用。
3.4益气活血中药复方对CVB_3病毒性心肌炎心肌细胞趋化因子CXCL12、SASH1、MCP-1、Rps4基因表达的影响:改良的SSH结果显示益气活血中药复方观察组中趋化因子CXCL12、SASH1、MCP-1、Rps4基因的表达比CVB_3病毒组中高,这一结果通过荧光RT-PCR得到验证。
实验结论:
1.利用体外培养的方法,成功建立了被CVB_3攻击的新生乳鼠原代心肌细胞的感染模型。
2.通过观察益气活血中药复方对CVB_3病毒性心肌炎心肌细胞趋化因子CXCL12、SASH1、MCP-1、Rps4基因表达的影响,进一步证实了以益气活血药为主组成的中药复方,具有多靶点、多层面和多作用的效果。
3.本课题从更深层次论证了益气活血法对病毒性心肌炎疗效的确切性,而益气活血中药复方是诊治病毒性心肌炎的有效方剂,揭示本方在VMC的治疗中具有广阔的应用前景。
Objective:Viral myocarditis refers to infection caused by a variety of in order to myocardial cell degeneration and necrosis, interstitial inflammatory cell infiltration and fibrous exudation for cardiac disease, major changes occur. Its pathogenicity to Coxsackie virus group B virus (CVB) is the main, and in the six CVB serotypes in, CVB3 Anopheles strong mind, therefore, the current principal for the establishment of viral infection in CVB3 myocarditis model to carry out the research, the subject of viral myocarditis to choose research subjects as a main reason is that this disease has a high self-harm, such as children and adults of all ages can be involved stage disease, acute period, and into a dilated the possibility of cardiomyopathy at the same time, can also be caused by small-scale outbreaks, and viral myocarditis in recent years the incidence of the rise is, therefore, against CVB3 viral myocarditis treatment mechanism appears imminent.
With that in mind, this research will establish a CVB3 mycocarditis cell infection model, through certain molecular biological technologies like the improved suppression subtractive hybridization (SSH), in order to explore the genetic expressive change of the chemotatic factors such as CXCL12、Sash1、small inducible cytokine A2、ribosomal protein S4, which are located in the attacked host cell and in the treatment group that use the method of Chinese Herbal boosting qi and enlivening blood formula (YiQi HuoXue Chinese Herbal Compound). The objective is to release the regulating function and the mode of Chinese Herbal boosting qi and enlivening blood formula to VMC, so as to further explore its biological effect and significance in the treatment of VMC, and to provide new theoretical basis and experimental basis. The research will also go further in showing that boosting qi and enlivening blood is a proven formula for treatment of VMC.
Material and method:
1.Research Materials
1.1 Experimental Animals Newborn 2-3d wistar rats (provided by LiaoNing Chinese Medical College Department of Experimental Animals)
1.2 Experimental Medicine and Reagents High Glucose DMEM(Gibco , USA) , Specialize fetal bovine serum(HaoYang Biological, TianJin), Penicillin (North China Pharmaceutical Co., Ltd., Shijiazhuang), Streptomycin sulfate (Merro Pharma, Dalian),Sodium bicarbonate (Tianjin Amino Acid Company, Tianjin),MTT(Sigma, USA), DMSO(Sigma, USA), Trypsin(Invitrogen, USA), PBS(Boster, WuHan). PFP (Santa, USA), ANT (Santa, USA), a-MHC(Abcam, USA), SABC immunohistochemistry (peroxidase)Kit (Boster, Wuhan), Antigen retrieval solution (Boster, Wuhan), Chromogenic DAB kit (Boster, Wuhan), Triton X-100(Solarbio, Beijing).
2.Research Methods
2.1 Yiqihuoxue cytotoxicity determination of compound Chinese medicine :Recovery from Hela cells by passage culture bottles after inoculation with 0.2ml of each hole to 96 hole cell culture plate, the home 37℃, 5% carbon dioxide incubator to cultivate, when Hela cells were adherent monolayer growth, the measurement Yiqihuoxue largest non-toxic dose of Chinese medicine compound. DMEM culture medium with the traditional Chinese medicine compound Yiqihuoxue injection started from the stock solution concentration of the preparation 11. Each hole 0.2ml, each concentration for 4-hole complex, plus an additional four control normal growth and pore fluid. In 24h, 48h observation of cell growth state, a reference hole normal cells to the cytopathic effect is not caused by the largest concentration of drug dilution largest concentration of non-toxic (TD0).
2.2 CVB3 Virulence Titration: In the 96-well plate dispose of the mono-layer Hella cell growth and wash each well twice with the HBSS solution. Using 2%fetal bovine serum as suspension, add ten concentrations of CVB3 virus diluted from 10-1 to 10-8. Each well with 0.1ml. On the 96 well plate, each concentration will be placed into four wells and four additional wells as a control. Each solution will be kept at 0.1ml and placed into a 5% Carbon Dioxide incubator and kept at 37oC. Cellular pathology will be observed at 24h and 48h. observation cell lesions.
2.3 Yiqihuoxue Chinese herbal compound on CVB3-induced myocardial cell death inhibition (MTT method) :Logarithmic phase from myocardial cells, 0.2ml of each hole by adding half the volume of the concentration of tissue infections myocytes CVB3 virus adsorption 2h. Suction disposable culture medium containing the virus, containing 2% fetal bovine serum to the maintenance of gently washing liquid on it, adding the largest non-toxic drug dosage from the initial dilution of the concentration of 8 Yiqihuoxue Chinese herbal compound containing the growth solution, 0.2 per hole ml, each concentration for 4-hole complex, a separate zero-hole. In 48h, each hole by adding 0.18ml DMEM culture medium, then add 0.02ml MTT solution into incubator to continue to foster 4h, carefully suction hole disposable culture medium, each hole by adding 0.15ml DMSO, the oscillation oscillator home 8min, in enzyme-linked immunosorbent assay detector 490 nm of the hole measured absorbance (OD).
2.4 the influence of YiQi HuoXue Chinese Herbal Compound to the genetic expression of Viral myocarditis,(VMC) chemotatic factors such as CXCL12, Sash1, MCP-1, ribosomal protein S4: through the improved suppression subtractive hybridization (SSH), the rat cardiac muscle cell CVB3 infection group and the gene that has a differential expression in YiQi HuoXue Chinese Herbal Compound group will be demeshed. The result wil be proved through FL RT-PCR.
3 Experimental Results:
3.1 Determination of Boosting Qi and Enlivening Blood Formula cytotoxicity: the maximum non-toxic dose for the formula is 7.813mg/ml.
3.2 CVB3 virulence titration: the infection rate of 50% cultured CVB3 virus cells is 1×10~(-4.5).
3.3 Boosting qi and enlivening blood formula inhibition of myocardial cell death from CVB3 virus(MTT method):use of maximum non-toxic dose boosting qi and enlivening blood formula on post-attack myocardial cells, had the largest absorption value, and in comparison with other dilutions there was a clear difference, p<0.001. This shows that the maximum non-toxic dose of boosting qi and enlivening blood formula has a clear inhibitory effect on CVB3 induced myocardial cell death.
3.4the influence of YiQi HuoXue Chinese Herbal Compound to the genetic expression of Viral myocarditis,(VMC) chemotatic factors such as CXCL12, Sash1, MCP-1, ribosomal protein S4: The results of SSH showed that genetic expression of CXCL12, Sash1, MCP-1, ribosomal protein S4 in treatment group were higher than that in CVB3 infection group. The results of fluorescent RT-PCR agreed with that of SSH.
Conclusion:
1.To primary neonatal rat cardiac myocytes in vitro methods, the establishment of the myocardial cells attack CVB3 infection model.
2.Through observing the influence of YiQi HuoXue Chinese Herbal Compound to the genetic expression of Viral myocarditis,(VMC) chemotatic factors such as CXCL12, Sash1, MCP-1, ribosomal protein S4, the multi-functional, multistrata, multi-targeting effect of YiQi HuoXue Chinese Herbal Compound have been confirmed.
3.The experiments further confirmed Yiqihuoxue VMC is an effective treatment of the law, and medicine Yiqihuoxue VMC compound is an effective prescription treatment, suggesting that this treatment in the VMC has broad application prospects.
引文
[1]Kashimura T, KodamaM, Hotta Y, et al . Spatiotemporal changes of coxsackievirus and adenovirus recep tor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat[ J ].VirchowsArch, 2003, 444 (3) : 283-292.
[2] Bowles NE , Ni J , K earney DL , et al . Detection of viruses in my ocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of my ocarditis in children and adults[J ] . J Am C oll Cardiol , 2003 , 6 , 42 (3) :466– 472.
[3] Bendig JW, O’Brien PS , Muir P , et al . Enterovirus sequences resembling coxsackievirus A2 detected in stool and spleen from a girl with fatal my ocarditis[J ] . J Med Virol , 2001 , 64 (4) :482– 486.
[4]Woodruff JF.Viral myocarditis,[J].Am J Pathol,1980,101:425-484.
[5]Reyes MP,Lerner AM.Coxsackievirus myocarditis-with special reference to acute and chronic effects.Prog Cardiovasc Dis 1985,27:373-394.
[6]Maisch B,Risti G.Hufnagel S,et al.Pathophysiology of viral myocarditis:The role of humoral immune response[J].Cardiovasc.Pathol.2002,11:112-122.
[7]Micheals AD,Lederman RJ,Macgregor JS,et al.Cardiovascular Involvement in AIDS.Current Problem in Cadiology,1997,22:111-148.
[8]Bergelson JM,Mohanty JG,Crowell RL,et al.Coxsackievirus B3 adapted to growth in RD cells binds to decay accelerating factor(CD55)[J].Virology,1995,6:1903-1906.
[9]Gradi A,Imataka H,Svitkin YV,et al.A novel functional human eukaryotic translation initiation factor 4G.Mol Cell Biol,1998,18:334-342.
[10]Kerekatte V,Deiper BD,Badorff C,et al.Cleavage of poly(A)-binding protein by coxsackievirus 2A protease in vitro and vive:another mechanism for host protein systhesize shut off[J].virology,1999,73:709-717.
[11]钱素娟,于维汉,周令望,等.Coxsackie B3病毒诱导人心肌细胞凋亡.中国地方病学杂志,1998,17:129-131.
[12]Basorff C,Lee GH,Laniphear BJ,et al.Enteroviral protease 2A cleaves dystrophin:evidence of cytoskeletal disruption in an acquired cardiomyopathy.NatureMedicine,1999,5:320-326.
[13] Hyypia T, K allajoki M, Maaronen M, et al . Pathogenetic differences between coxsackie A and B virus in fections in newborn mice [ J ] . Virus Res ,1993 , 27 (1) :71– 78.
[14]Cars on SD. Recep tor for the group B coxsackieviruses and adenoviruses : CAR[ J ]. RevMed Virol, 2001, 11 (4) : 219- 226.
[15]SchmidtkeM, Selinka HC, Heim A, et al . Attachment of coxsackievirus B3 variants t o various cell lines : mapp ing of phenotypic difference to cap sid p r otein VP1 [ J ]. J Virol, 2000, 275 ( 1 ) :77-88.
[16] Cheung PK, Yuan J , Zhang HM, et al . S pecific interactions of mouse organ proteins with the 5’untranslated region of coxsackievirus B3 : P otential determinants of viral tissue tropism[J ] . J Med Virol ,2005 , 77 (3) :414 - 424.
[17] Brady WJ , Fergus on JD , Ullman EA , et al . My ocarditis : emergency department recognition and management [J ] . Emerg Med Clin North Am , 2004 , 22 (4) :865– 885.
[18] Futamatsu H , Suzuki J , K osuge H , et al . Attenuation of experimental autoimmune my ocarditis by blocking activated T cells through inducible costimulatory molecule pathway [ J ] . CardiovascRes , 2003 , 59 (1) :95– 104.
[19]K anda T, Takahashi T, I toh T, et al . Upregulation of cardiac ghrelin mRNA in leptin2deficient and leptin receptor2deficient mice with viral my ocarditis[J ] . J Int Med Res , 2003 ,31 (6) :503– 508.
[20] Si X, McManus BM, Zhang J , et al . Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin proteasome pathway[J ] . J Virol , 2005 , 79 (13) :8014 -8023.
[21] Huber S. T cells in coxsackievirus2induced my ocarditis [ J ] . Viral Immunol , 2004 , 17 (2) :152– 164.
[22] Maier R , K rebs P , Ludewig B. Immunopathological basis of virus-induced my ocarditis[J ] . Clin Dev Immunol , 2004 ,11 (1) :1– 5.
[23]Zlotnic A, Yoshie O. Chemokines : a new classification system and their role in immunity[ J ]. I mmunity, 2000, 12 (10) : 121-126.
[24]Gerard C, Rollins BJ . Chemokines and disease [ J ]. Nat I mmunol,2001, 2 (11) : 108-115.
[25]宁娟,李永宏.病毒性心肌炎的发病机制[ J ].医学综述, 2008, 14( 9):1349-1351.
[26]Whitt on JL, Feuer R. Myocarditismicrobes and autoimmunity[ J ].Aut oimmunity, 2004, 37 (5) : 375- 386.
[27]Caforio AL. Novel organ2s pecific circulating cardiac aut oantibodies in dilated cardiomyopathy [ J ]. J Am Coll Cardio, 1990, 15 ( 7 ) :1527- 1534.
[28]Kuhl U,MelznerB, SchaferB, et al . The Ca2 channel as cardiac autogantigen[ J ]. Eur Heart J, 1991, 12 ( Supp l D) : 99-104.
[29]Liao YH, Cheng LX, Da SP, et al . Autoantibodies against ADP /ATP carrier from patientswith dilated cardiomyopathy increase activity of voltage2 dependent Ca channels in is olated cardiac myocytes[ J ]. Blood Press, 1996, 3 ( Supp l) : 41-44.
[30]Tharaux PL, Chatziantoniou C, Fakhouri F, et al . Angi otensinⅡactivates collagenⅠgene through a mechanism involving the MAP /ER kinase pathway[ J ]. Hypertension, 2000, 36 (11) : 330- 336.
[31]Ruiz2 OrtegaM, Lorenz o O, Ruperez M, et al . AngiotensinⅡactives nuclear transcrip tion factor-Kappa B in aorta of normal rats and in vascular smooth muscle cells of ATl knockout mice [ J ].NephrolDial Trans p lant, 2002, 16 ( Supp l 1) : 27-33.
[32]Etoh T, Joffs C, Deschamp s A I , et al . Myocardial and interstitial matrixmetallopr oteinase activity after acute myocardial infaction in pigs [ J ]. Am J Physiol Heart Circ Physi ol, 2001, 281 ( 3 ) :H987-H994.
[33]Kasahara A, HayashiN,Mochizuki K, et al . Circulatingmatrixmetalloproteinase-2 and tissue inhibitor of metallop roteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relati onshi p t o interferon res ponse [ J ]. J Hepatol, 1997, 26 ( 2 ) :574-583.
[34]BennettMR. Apop tosis in the cardi ovascular system [ J ]. Heart,2002, 87 (2) : 480- 487.
[35]陈慰峰.医学免疫学[M ]. 4版.北京:人民卫生出版社, 2004:235- 236.
[36] Opavsky MA , Martino T, Rabinovitch M, et al . Enhanced ERK -1/2 activation in mice susceptible to coxsackievirus induced my ocarditis[J ] . J Clin Invest ,2002 ,109 (12) :1561-1569.
[37]彭健豪,张连峰.病毒性心肌炎的发病机制[J ] .中国比较医学杂志,2006,16 (1) :54-57.
[38]郑智,李树生.猝死防治学[M ].北京:中国医药科技出版社,2004: 7.
[39]吴良昌.病毒性心肌炎的治疗与预防[J ] .中国民族民间医药,2009,3:79
[40]李建丰.病毒性心肌炎的中医治疗[J].中国医药导报,2006,3(17 ):115.
[41]许裕荣,何兴国,李应伟等,中西医结合治疗病毒性心肌炎30例临床观察[J].中国现代医生,2007,45(8):65-84.
[42]周红艳.病毒性心肌炎的治疗[J].中外医疗,2008,7:79
[43]王振涛.病毒性心肌炎的分期辨治〔J〕.河南中医,2003;23(2):44~46.
[44]李克忠.病毒性心肌炎的分期辨治〔J〕河南中医学院学报,2003;5(3):55~56.
[45]杨竹芹,董艳霞.病毒性心肌炎的分型治疗〔J〕.中医药信息,1994;(3):22
[46]张志明.病毒性心肌炎分三期施治〔J〕河南中医,1998;18(1):26.
[47]中华人民共和国卫生部药政局,中药新药临床研究指导原则〔M〕.中华人民共和国卫生部,1997.
[48]王永炎,鲁兆麟.中医内科学〔M〕.北京:人民卫生出版社,2002年;第一版.
[49]徐漫漫.中医药治疗病毒性心肌炎研究近况〔J〕.山东中医杂志,1999;18(9):431.
[50]成淑凤,张春萍.辨证治疗小儿病毒性心肌炎体会〔J〕.中医研究,19%;9(4):21.
[51]焦增锦.中西医临床心血管病学〔M].北京:中国中医药出版社,2000;581~597.
[52]江扬清.中西医结合内科研究〔M].北京:北京出版社,437~446.
[53]唐文涛.辨证治疗病毒性心肌炎85例〔J〕.实用中医药杂志,1998;14(10):8.
[54]冯振兴.辨证分型治疗病毒性心肌炎98例〔J〕.安徽中医临床杂志,1996;8(1):9·
[55]史小青.中医辨证治疗急性病毒性心肌炎的临床体会〔J〕四川中医,2002;20(10):22~23.
[56]黄永生.病毒性心肌炎的辨证论治〔J〕.长春中医学院学报,2003;19(3):38~39.
[57]陈宝义.小儿急性病毒性心肌炎65例中西药对照治疗观察〔J〕.中国中西医结合杂志,2003:13(2):126.
[58]戴世银,吴小燕.小儿病毒性心肌炎证治体会仁〔J〕.中国中医急症,2002:n(2):151~152.
[59]田淑芳,刘弼臣.治疗小儿病毒性心肌炎的经验〔J〕.河北中医,1994;16(6):13.
[60]杨占秋.临床病毒学,北京:中国中医药出版社,2000年5月,第一版
[61]钟飞,杜九中,于小华,等.黄芪甲甙对病毒性心肌炎细胞凋亡作用的研究.南华大学学报,2004,32(1):17-19.
[62]李双杰,张召才,陈瑞珍,等.黄芪甲苷治疗BALB/C小鼠CVB3病毒性心肌炎疗效研究.中华实用中西医杂志,2004,4(7):681-683.
[63]彭华,刘亚黎,胡晓华,等.黄芪对病毒性心肌炎心肌细胞信号转导及转录活化抑制因子3信号通路的影响.实用儿科临床杂志,2005,20(3):218-220.
[64]于小华,李双杰,张新刚,等.黄芪甲甙对病毒性心肌炎小鼠心肌组织蛋白酶B mRNA表达的影响.实用儿科临床杂志,2005,20(7):622-624.
[65]吴凡,邱汉婴,董继华,等.黄芪对病毒性心肌炎心脏细胞因子mRNA表达的影响.临床心血管病杂志,2004,20(3):165-168.
[66]焦艳,闻杰,于晓红,等.膜荚黄芪茎叶总黄酮对小鼠细胞免疫功能的影响.中国中西医结合杂志,1999,19(6):356.
[67]刘冠男,陈国权,赵明.黄芪总黄酮对病毒性心肌炎小鼠心脏血流动力学及心肌细胞钙电流的作用.中国心血管杂志,2008,13(6):431-433.
[68]刘恭鑫,杨英珍,顾全保,等.黄芪对感染病毒大鼠心肌细胞钙通道及钠钙交换载体的效应.中国病理生理杂志,1999,15(7):591.
[69]李佩玲,黄显湘.丹参对病毒性心肌炎血液动力学的改善.实用儿科临床杂质,1995,10(1):40-41.
[70]丰爱军,丰爱娟.复方丹参联合辅酶Q10治疗小儿病毒性心肌炎疗效观察.黑龙江医药科学,2007,30(3):90.
[71]冯永歌.丹参辅助治疗小儿病毒性心肌炎的临床疗效观察.中外健康文摘,2008,5(2):41-42.
[72]徐海燕,马沛然.西洋参对小鼠病毒性心肌炎的疗效及机制.山东中医药大学学报,2002,26(6):458-461.
[73]史玲艾,丁翠,杜静,等.莪术油注射液治疗小儿病毒性心肌炎疗效观察.河北中医,2004,26(3):226.
[74]张松,葛均波,张卉,等.三七总苷治疗病毒性心肌炎的实验研究.中华中医药学刊,2009,27(4):807-809.
[75]李凤新,孙振国,孙非.虎杖总蒽醌提取物对病毒性心肌炎主要致病病毒抗病毒谱的研究.中成药,2008,30(1):123-124.
[76]王卫华,肖红,陈科力,等.虎杖提取液抗柯萨奇病毒B3的实验研究.湖南中医杂志,2001,23(9):47-48.
[77]宋军华,王述昀,牟道玉,等.虎杖苷单体对急性病毒性心肌炎的影响.滨州医学院学报,2008,31(2):95-98.
[78]魏剑平.“益气养阴法”治疗小儿病毒性心肌炎迁延期的疗效观察.甘肃中医,2007,20(7):33-34.
[79]付廷斌.补心益气汤治疗病毒性心肌炎32例.中国中医急症,2007,16(2):230.
[80]王红.益气养阴方治疗病毒性心肌炎35例.陕西中医,2007,28(10):1290-1291.
[81]曹平敏.安心汤治疗病毒性心肌炎所致心律失常临床观察.河北中医,2004,26(2):105-106.
[82]王利民,宋桂叶.炙甘草汤加减治疗病毒性心肌炎临床研究.河南中医学院学报,2008,23(3):35-36.
[83]林杨,林飞进.补阳还五汤加味治疗病毒性心肌炎36例.北京中医,2006,25(3):162-163.
[84]梁巧霞.益心解毒化瘀汤治疗病毒性心肌炎66例.江苏中医药,2007,39(9):32.
[85]王荣生,张金钊.解毒涤痰汤治疗病毒性心肌炎心肌损伤46例临床研究.中外医疗,2008,17:17-18.
[86]朱文锋.国家标准应用中医内科疾病诊疗常规〔J〕.湖南科学技术出版社,1999:第一版,243~245.
[87] Diatchenko L, Lau YF, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. ProcNatl Acad Sci U S A, 1996, 93 (12)∶6025-6030.
[88]Yang G Pet al. Nucleic Acids Res, 1999; 27(6): 1517
[89] Rauhala H, Porkka K, Tolonen T,et al. Dual-specificity phosphatase 1 and serum /glucocorticoid-regulated kinase are downregulated in prostate cancer[ J]. Int J Cancer,2005, 117: 738-745.
[90]AsaiT, Tomita Y,Nakatsuka S. VCP(p97) regulates NF-kappa B sigaling pathway,which is important formetastasisof osteosarcoma cell line[ J]. Jpn J CancerRes, 2002, 93:296-304.
[91]范保星,笪冀平,张开泰,等.肺癌诊断基因的初步筛选[J].循证医学, 2002, 2: 75-79.
[92] Zhang Z, DuBois R. Detection of differentially expressedgenes in human colon carcinoma cells treated with a selec-tive COX-2 inhibitor[J].Onogene, 2001, 20:4450-4456.
[93]王涛,陆应麟,刘爽,等.抑制消减杂交技术克隆肺癌转移调控基因[J].中华肿瘤杂志, 2001, 23: 296-300.
[94]Zanders E Det al. J Immunol Methods, 2000; 233:131
[95]LiC, Chen S, ChenW,et al. Detection of gene expressionalteration ofmyeloma cells treatedwith arsenic trioxide[J].Zhonghua XueYe Xue Za Zh,i 2005, 26: 209-213.
[96]Hufton S Eet al. FEBS Lett, 1999; 463(1-2): 77
[97]Li S Ret al. Biochem Biophys Res Commum, 2000;271(2): 537
[98]Nemeth Eet al. J Mol Endocrinol, 1998; 20(1): 151
[100]Stubbs A Pet al. Am J Pathol, 1999; 154(5): 1335
[99]Nemeth Eet al. Am J Obstet Gynecol, 2000; 182(1pt1): 60
[101]Wang Xet al. Brain Res Mol Brain Res, 1999; 71(2):304
[102]Johnatty SE, Dyck JR, Michael LH, et al. Identification of genes regulated during mechanical load-induced cardiac hypertrophy[J] .J Mol Cell Cardiol, 2000,32(5):805-815.
[103]Diachenko L,Lau YC,CamPbellAp,Chenchik A,MoqadamF,HuangB,LukyanovS,LukyanovK,GurskayaN,SverdlovED,SiebertpD.suppressionsubtractive hybridization:amethod for generating differentially regulated or tissue-specific cDNAProbes and libraries.Proc Natl Acad Sci USA 1996;93:6025-6030.
[104]Han FC,GongM,NgHC,Ho B.Identifieation of H pylori strain Specific DNA sequences between two clinical isolates from NUD And gastric ulcer bySSH.World J Gastroenterol 2003,9:1747-1751.
[105]陈忠斌,杨静,王华,等.应用抑制性消减杂交技术筛选流感病毒感染宿主应答基因.中国生物化学与分子生物学报, 2003,19: 156-167.
[106] Chim SS. Fung K, Wage MM, et al. Expression of replication factor C 40-kDa subunit is down-regulated during neonatal development in rat ventricula myocardium[JJ J Cell Biochem.2000.78(4):533-540.
[107]Gottlieb PD, Pierce SA. Sims Rl, et al.Bop encodes a muscle-restricted protein containing MYND.and SET domains and is essential for cardiac differentiatian and morphogenesis[ J ] . Nat Genet, 2002, 3l (1) : 25-32.
[108]The SMART PCR cDNA synthesis Kit user manual[Z].BD Biosciences Clontech.USA, 2003,7:7.
[109]王吉村,药立波,赵忠良。筛选差异表达基因和蛋白质的方法进展。生物化学与生物物理进展,2001;28(1):33—36
[110]朱理安,关瑞锦,胡锡衷。病毒性心肌炎细胞感染模型的建立。福建医科大学学报,2000;34(3):224—227
[111]程志清,刘强。用血清药理学方法观察清心饮对培养大鼠心肌细胞感染柯萨奇B3病毒的影响,中医杂志,1999;40(1):47—49
[112]郭良集.著名老中医张伯臾对心肌炎恢复期繁荣治疗经验[J].上海中医药杂志, 1984, (10): 4.
[113]王雪峰,刘坊,李冬梅.黄芪对心肌炎小鼠IL-2及Fasl的表达影响[J].辽宁中医杂志. 2001, 28(7)∶439-440.
[114]Cochran BH.Rcffcl AC and Stiles CD.Molecular cloning of gcne sequences regulated by platelet-derived growth factor.Cell,1983,33:939—947
[115]Yoshimura T,Yulff,i N,Moore SK,ct a1.Human monocyte chemoattractant protein-1(MCP一1):Full—length Cdna cloning, expression in mitogen—stimulated blood mononuclear leukocytes,and sequedce similarity to mouse competence gene JE.FEBS LETTERS.1989,244:487-493
[116]鲍荣辉,刘先哲.单核细胞趋化蛋白研究进展[J].综述与展.2006,35(4):58-60
[117]Ducharme L A ct al. Eur J lmmunol,1992; 22: 2603-2607
[118]Proost P,Wuyts A,Van Damme J.Human monocyte chemotactic protein-2 and-3: structural and functional comparison with MCP-1.J of Leukocyte Biology,1996,59:67-75
[119]Uchiumi,T.,M.Kikuchi,andK.Ogata,Cross-linking study on Protein neighborhoods at the subunit interface of rat liver ribosomes with2- iminothiolane.J Biol Chem,1986.261(21):p. 9663-7.
[120]Westermann,P.and O.Nygard,The spatial arrangement of thecomplex between eukaryotic initiation faetor eIF-3 and 40s ribosomal subunit. Cross-linking between factor and ribosomal proteins. Biochim BioPhys Aeta,1983.741(l):P.103-8.
[121]Fisher,E.M.,et al.,Homologous ribosomal protein genes on the Human X and Y chromosomes: escape from X inactivation and Possible implications for Tumer syndrome.Cell,1990.63(6):P. 1205-18.
[122]Synetos,D.,M.D.Dabeva,and J.R.Warner,The yeast ribosomal proteinS7 and its genes. J Biol Chem,1992.267(5):p.3008-13.
[123]Bochmann MF, KopfM, Mansland BJ, et a.l Chemokines: more than just road signs[J]. NatRev Immuno,l2006,6(2):159-164.
[124]Moepps B,Frodl R,Rodewald H,et al. Two murine homologues of the human chemokine receptor CXCR4 mediating stromal cell-derived factor 1 alpha activation of Gi2 are differentially expressed in vivo[J],Eur J Immuno1,1997,27;2102-2112.
[2] Bowles NE , Ni J , K earney DL , et al . Detection of viruses in my ocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of my ocarditis in children and adults[J ] . J Am C oll Cardiol , 2003 , 6 , 42 (3) :466– 472.
[3] Bendig JW, O’Brien PS , Muir P , et al . Enterovirus sequences resembling coxsackievirus A2 detected in stool and spleen from a girl with fatal my ocarditis[J ] . J Med Virol , 2001 , 64 (4) :482– 486.
[4]Woodruff JF.Viral myocarditis,[J].Am J Pathol,1980,101:425-484.
[5]Reyes MP,Lerner AM.Coxsackievirus myocarditis-with special reference to acute and chronic effects.Prog Cardiovasc Dis 1985,27:373-394.
[6]Maisch B,Risti G.Hufnagel S,et al.Pathophysiology of viral myocarditis:The role of humoral immune response[J].Cardiovasc.Pathol.2002,11:112-122.
[7]Micheals AD,Lederman RJ,Macgregor JS,et al.Cardiovascular Involvement in AIDS.Current Problem in Cadiology,1997,22:111-148.
[8]Bergelson JM,Mohanty JG,Crowell RL,et al.Coxsackievirus B3 adapted to growth in RD cells binds to decay accelerating factor(CD55)[J].Virology,1995,6:1903-1906.
[9]Gradi A,Imataka H,Svitkin YV,et al.A novel functional human eukaryotic translation initiation factor 4G.Mol Cell Biol,1998,18:334-342.
[10]Kerekatte V,Deiper BD,Badorff C,et al.Cleavage of poly(A)-binding protein by coxsackievirus 2A protease in vitro and vive:another mechanism for host protein systhesize shut off[J].virology,1999,73:709-717.
[11]钱素娟,于维汉,周令望,等.Coxsackie B3病毒诱导人心肌细胞凋亡.中国地方病学杂志,1998,17:129-131.
[12]Basorff C,Lee GH,Laniphear BJ,et al.Enteroviral protease 2A cleaves dystrophin:evidence of cytoskeletal disruption in an acquired cardiomyopathy.NatureMedicine,1999,5:320-326.
[13] Hyypia T, K allajoki M, Maaronen M, et al . Pathogenetic differences between coxsackie A and B virus in fections in newborn mice [ J ] . Virus Res ,1993 , 27 (1) :71– 78.
[14]Cars on SD. Recep tor for the group B coxsackieviruses and adenoviruses : CAR[ J ]. RevMed Virol, 2001, 11 (4) : 219- 226.
[15]SchmidtkeM, Selinka HC, Heim A, et al . Attachment of coxsackievirus B3 variants t o various cell lines : mapp ing of phenotypic difference to cap sid p r otein VP1 [ J ]. J Virol, 2000, 275 ( 1 ) :77-88.
[16] Cheung PK, Yuan J , Zhang HM, et al . S pecific interactions of mouse organ proteins with the 5’untranslated region of coxsackievirus B3 : P otential determinants of viral tissue tropism[J ] . J Med Virol ,2005 , 77 (3) :414 - 424.
[17] Brady WJ , Fergus on JD , Ullman EA , et al . My ocarditis : emergency department recognition and management [J ] . Emerg Med Clin North Am , 2004 , 22 (4) :865– 885.
[18] Futamatsu H , Suzuki J , K osuge H , et al . Attenuation of experimental autoimmune my ocarditis by blocking activated T cells through inducible costimulatory molecule pathway [ J ] . CardiovascRes , 2003 , 59 (1) :95– 104.
[19]K anda T, Takahashi T, I toh T, et al . Upregulation of cardiac ghrelin mRNA in leptin2deficient and leptin receptor2deficient mice with viral my ocarditis[J ] . J Int Med Res , 2003 ,31 (6) :503– 508.
[20] Si X, McManus BM, Zhang J , et al . Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin proteasome pathway[J ] . J Virol , 2005 , 79 (13) :8014 -8023.
[21] Huber S. T cells in coxsackievirus2induced my ocarditis [ J ] . Viral Immunol , 2004 , 17 (2) :152– 164.
[22] Maier R , K rebs P , Ludewig B. Immunopathological basis of virus-induced my ocarditis[J ] . Clin Dev Immunol , 2004 ,11 (1) :1– 5.
[23]Zlotnic A, Yoshie O. Chemokines : a new classification system and their role in immunity[ J ]. I mmunity, 2000, 12 (10) : 121-126.
[24]Gerard C, Rollins BJ . Chemokines and disease [ J ]. Nat I mmunol,2001, 2 (11) : 108-115.
[25]宁娟,李永宏.病毒性心肌炎的发病机制[ J ].医学综述, 2008, 14( 9):1349-1351.
[26]Whitt on JL, Feuer R. Myocarditismicrobes and autoimmunity[ J ].Aut oimmunity, 2004, 37 (5) : 375- 386.
[27]Caforio AL. Novel organ2s pecific circulating cardiac aut oantibodies in dilated cardiomyopathy [ J ]. J Am Coll Cardio, 1990, 15 ( 7 ) :1527- 1534.
[28]Kuhl U,MelznerB, SchaferB, et al . The Ca2 channel as cardiac autogantigen[ J ]. Eur Heart J, 1991, 12 ( Supp l D) : 99-104.
[29]Liao YH, Cheng LX, Da SP, et al . Autoantibodies against ADP /ATP carrier from patientswith dilated cardiomyopathy increase activity of voltage2 dependent Ca channels in is olated cardiac myocytes[ J ]. Blood Press, 1996, 3 ( Supp l) : 41-44.
[30]Tharaux PL, Chatziantoniou C, Fakhouri F, et al . Angi otensinⅡactivates collagenⅠgene through a mechanism involving the MAP /ER kinase pathway[ J ]. Hypertension, 2000, 36 (11) : 330- 336.
[31]Ruiz2 OrtegaM, Lorenz o O, Ruperez M, et al . AngiotensinⅡactives nuclear transcrip tion factor-Kappa B in aorta of normal rats and in vascular smooth muscle cells of ATl knockout mice [ J ].NephrolDial Trans p lant, 2002, 16 ( Supp l 1) : 27-33.
[32]Etoh T, Joffs C, Deschamp s A I , et al . Myocardial and interstitial matrixmetallopr oteinase activity after acute myocardial infaction in pigs [ J ]. Am J Physiol Heart Circ Physi ol, 2001, 281 ( 3 ) :H987-H994.
[33]Kasahara A, HayashiN,Mochizuki K, et al . Circulatingmatrixmetalloproteinase-2 and tissue inhibitor of metallop roteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relati onshi p t o interferon res ponse [ J ]. J Hepatol, 1997, 26 ( 2 ) :574-583.
[34]BennettMR. Apop tosis in the cardi ovascular system [ J ]. Heart,2002, 87 (2) : 480- 487.
[35]陈慰峰.医学免疫学[M ]. 4版.北京:人民卫生出版社, 2004:235- 236.
[36] Opavsky MA , Martino T, Rabinovitch M, et al . Enhanced ERK -1/2 activation in mice susceptible to coxsackievirus induced my ocarditis[J ] . J Clin Invest ,2002 ,109 (12) :1561-1569.
[37]彭健豪,张连峰.病毒性心肌炎的发病机制[J ] .中国比较医学杂志,2006,16 (1) :54-57.
[38]郑智,李树生.猝死防治学[M ].北京:中国医药科技出版社,2004: 7.
[39]吴良昌.病毒性心肌炎的治疗与预防[J ] .中国民族民间医药,2009,3:79
[40]李建丰.病毒性心肌炎的中医治疗[J].中国医药导报,2006,3(17 ):115.
[41]许裕荣,何兴国,李应伟等,中西医结合治疗病毒性心肌炎30例临床观察[J].中国现代医生,2007,45(8):65-84.
[42]周红艳.病毒性心肌炎的治疗[J].中外医疗,2008,7:79
[43]王振涛.病毒性心肌炎的分期辨治〔J〕.河南中医,2003;23(2):44~46.
[44]李克忠.病毒性心肌炎的分期辨治〔J〕河南中医学院学报,2003;5(3):55~56.
[45]杨竹芹,董艳霞.病毒性心肌炎的分型治疗〔J〕.中医药信息,1994;(3):22
[46]张志明.病毒性心肌炎分三期施治〔J〕河南中医,1998;18(1):26.
[47]中华人民共和国卫生部药政局,中药新药临床研究指导原则〔M〕.中华人民共和国卫生部,1997.
[48]王永炎,鲁兆麟.中医内科学〔M〕.北京:人民卫生出版社,2002年;第一版.
[49]徐漫漫.中医药治疗病毒性心肌炎研究近况〔J〕.山东中医杂志,1999;18(9):431.
[50]成淑凤,张春萍.辨证治疗小儿病毒性心肌炎体会〔J〕.中医研究,19%;9(4):21.
[51]焦增锦.中西医临床心血管病学〔M].北京:中国中医药出版社,2000;581~597.
[52]江扬清.中西医结合内科研究〔M].北京:北京出版社,437~446.
[53]唐文涛.辨证治疗病毒性心肌炎85例〔J〕.实用中医药杂志,1998;14(10):8.
[54]冯振兴.辨证分型治疗病毒性心肌炎98例〔J〕.安徽中医临床杂志,1996;8(1):9·
[55]史小青.中医辨证治疗急性病毒性心肌炎的临床体会〔J〕四川中医,2002;20(10):22~23.
[56]黄永生.病毒性心肌炎的辨证论治〔J〕.长春中医学院学报,2003;19(3):38~39.
[57]陈宝义.小儿急性病毒性心肌炎65例中西药对照治疗观察〔J〕.中国中西医结合杂志,2003:13(2):126.
[58]戴世银,吴小燕.小儿病毒性心肌炎证治体会仁〔J〕.中国中医急症,2002:n(2):151~152.
[59]田淑芳,刘弼臣.治疗小儿病毒性心肌炎的经验〔J〕.河北中医,1994;16(6):13.
[60]杨占秋.临床病毒学,北京:中国中医药出版社,2000年5月,第一版
[61]钟飞,杜九中,于小华,等.黄芪甲甙对病毒性心肌炎细胞凋亡作用的研究.南华大学学报,2004,32(1):17-19.
[62]李双杰,张召才,陈瑞珍,等.黄芪甲苷治疗BALB/C小鼠CVB3病毒性心肌炎疗效研究.中华实用中西医杂志,2004,4(7):681-683.
[63]彭华,刘亚黎,胡晓华,等.黄芪对病毒性心肌炎心肌细胞信号转导及转录活化抑制因子3信号通路的影响.实用儿科临床杂志,2005,20(3):218-220.
[64]于小华,李双杰,张新刚,等.黄芪甲甙对病毒性心肌炎小鼠心肌组织蛋白酶B mRNA表达的影响.实用儿科临床杂志,2005,20(7):622-624.
[65]吴凡,邱汉婴,董继华,等.黄芪对病毒性心肌炎心脏细胞因子mRNA表达的影响.临床心血管病杂志,2004,20(3):165-168.
[66]焦艳,闻杰,于晓红,等.膜荚黄芪茎叶总黄酮对小鼠细胞免疫功能的影响.中国中西医结合杂志,1999,19(6):356.
[67]刘冠男,陈国权,赵明.黄芪总黄酮对病毒性心肌炎小鼠心脏血流动力学及心肌细胞钙电流的作用.中国心血管杂志,2008,13(6):431-433.
[68]刘恭鑫,杨英珍,顾全保,等.黄芪对感染病毒大鼠心肌细胞钙通道及钠钙交换载体的效应.中国病理生理杂志,1999,15(7):591.
[69]李佩玲,黄显湘.丹参对病毒性心肌炎血液动力学的改善.实用儿科临床杂质,1995,10(1):40-41.
[70]丰爱军,丰爱娟.复方丹参联合辅酶Q10治疗小儿病毒性心肌炎疗效观察.黑龙江医药科学,2007,30(3):90.
[71]冯永歌.丹参辅助治疗小儿病毒性心肌炎的临床疗效观察.中外健康文摘,2008,5(2):41-42.
[72]徐海燕,马沛然.西洋参对小鼠病毒性心肌炎的疗效及机制.山东中医药大学学报,2002,26(6):458-461.
[73]史玲艾,丁翠,杜静,等.莪术油注射液治疗小儿病毒性心肌炎疗效观察.河北中医,2004,26(3):226.
[74]张松,葛均波,张卉,等.三七总苷治疗病毒性心肌炎的实验研究.中华中医药学刊,2009,27(4):807-809.
[75]李凤新,孙振国,孙非.虎杖总蒽醌提取物对病毒性心肌炎主要致病病毒抗病毒谱的研究.中成药,2008,30(1):123-124.
[76]王卫华,肖红,陈科力,等.虎杖提取液抗柯萨奇病毒B3的实验研究.湖南中医杂志,2001,23(9):47-48.
[77]宋军华,王述昀,牟道玉,等.虎杖苷单体对急性病毒性心肌炎的影响.滨州医学院学报,2008,31(2):95-98.
[78]魏剑平.“益气养阴法”治疗小儿病毒性心肌炎迁延期的疗效观察.甘肃中医,2007,20(7):33-34.
[79]付廷斌.补心益气汤治疗病毒性心肌炎32例.中国中医急症,2007,16(2):230.
[80]王红.益气养阴方治疗病毒性心肌炎35例.陕西中医,2007,28(10):1290-1291.
[81]曹平敏.安心汤治疗病毒性心肌炎所致心律失常临床观察.河北中医,2004,26(2):105-106.
[82]王利民,宋桂叶.炙甘草汤加减治疗病毒性心肌炎临床研究.河南中医学院学报,2008,23(3):35-36.
[83]林杨,林飞进.补阳还五汤加味治疗病毒性心肌炎36例.北京中医,2006,25(3):162-163.
[84]梁巧霞.益心解毒化瘀汤治疗病毒性心肌炎66例.江苏中医药,2007,39(9):32.
[85]王荣生,张金钊.解毒涤痰汤治疗病毒性心肌炎心肌损伤46例临床研究.中外医疗,2008,17:17-18.
[86]朱文锋.国家标准应用中医内科疾病诊疗常规〔J〕.湖南科学技术出版社,1999:第一版,243~245.
[87] Diatchenko L, Lau YF, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. ProcNatl Acad Sci U S A, 1996, 93 (12)∶6025-6030.
[88]Yang G Pet al. Nucleic Acids Res, 1999; 27(6): 1517
[89] Rauhala H, Porkka K, Tolonen T,et al. Dual-specificity phosphatase 1 and serum /glucocorticoid-regulated kinase are downregulated in prostate cancer[ J]. Int J Cancer,2005, 117: 738-745.
[90]AsaiT, Tomita Y,Nakatsuka S. VCP(p97) regulates NF-kappa B sigaling pathway,which is important formetastasisof osteosarcoma cell line[ J]. Jpn J CancerRes, 2002, 93:296-304.
[91]范保星,笪冀平,张开泰,等.肺癌诊断基因的初步筛选[J].循证医学, 2002, 2: 75-79.
[92] Zhang Z, DuBois R. Detection of differentially expressedgenes in human colon carcinoma cells treated with a selec-tive COX-2 inhibitor[J].Onogene, 2001, 20:4450-4456.
[93]王涛,陆应麟,刘爽,等.抑制消减杂交技术克隆肺癌转移调控基因[J].中华肿瘤杂志, 2001, 23: 296-300.
[94]Zanders E Det al. J Immunol Methods, 2000; 233:131
[95]LiC, Chen S, ChenW,et al. Detection of gene expressionalteration ofmyeloma cells treatedwith arsenic trioxide[J].Zhonghua XueYe Xue Za Zh,i 2005, 26: 209-213.
[96]Hufton S Eet al. FEBS Lett, 1999; 463(1-2): 77
[97]Li S Ret al. Biochem Biophys Res Commum, 2000;271(2): 537
[98]Nemeth Eet al. J Mol Endocrinol, 1998; 20(1): 151
[100]Stubbs A Pet al. Am J Pathol, 1999; 154(5): 1335
[99]Nemeth Eet al. Am J Obstet Gynecol, 2000; 182(1pt1): 60
[101]Wang Xet al. Brain Res Mol Brain Res, 1999; 71(2):304
[102]Johnatty SE, Dyck JR, Michael LH, et al. Identification of genes regulated during mechanical load-induced cardiac hypertrophy[J] .J Mol Cell Cardiol, 2000,32(5):805-815.
[103]Diachenko L,Lau YC,CamPbellAp,Chenchik A,MoqadamF,HuangB,LukyanovS,LukyanovK,GurskayaN,SverdlovED,SiebertpD.suppressionsubtractive hybridization:amethod for generating differentially regulated or tissue-specific cDNAProbes and libraries.Proc Natl Acad Sci USA 1996;93:6025-6030.
[104]Han FC,GongM,NgHC,Ho B.Identifieation of H pylori strain Specific DNA sequences between two clinical isolates from NUD And gastric ulcer bySSH.World J Gastroenterol 2003,9:1747-1751.
[105]陈忠斌,杨静,王华,等.应用抑制性消减杂交技术筛选流感病毒感染宿主应答基因.中国生物化学与分子生物学报, 2003,19: 156-167.
[106] Chim SS. Fung K, Wage MM, et al. Expression of replication factor C 40-kDa subunit is down-regulated during neonatal development in rat ventricula myocardium[JJ J Cell Biochem.2000.78(4):533-540.
[107]Gottlieb PD, Pierce SA. Sims Rl, et al.Bop encodes a muscle-restricted protein containing MYND.and SET domains and is essential for cardiac differentiatian and morphogenesis[ J ] . Nat Genet, 2002, 3l (1) : 25-32.
[108]The SMART PCR cDNA synthesis Kit user manual[Z].BD Biosciences Clontech.USA, 2003,7:7.
[109]王吉村,药立波,赵忠良。筛选差异表达基因和蛋白质的方法进展。生物化学与生物物理进展,2001;28(1):33—36
[110]朱理安,关瑞锦,胡锡衷。病毒性心肌炎细胞感染模型的建立。福建医科大学学报,2000;34(3):224—227
[111]程志清,刘强。用血清药理学方法观察清心饮对培养大鼠心肌细胞感染柯萨奇B3病毒的影响,中医杂志,1999;40(1):47—49
[112]郭良集.著名老中医张伯臾对心肌炎恢复期繁荣治疗经验[J].上海中医药杂志, 1984, (10): 4.
[113]王雪峰,刘坊,李冬梅.黄芪对心肌炎小鼠IL-2及Fasl的表达影响[J].辽宁中医杂志. 2001, 28(7)∶439-440.
[114]Cochran BH.Rcffcl AC and Stiles CD.Molecular cloning of gcne sequences regulated by platelet-derived growth factor.Cell,1983,33:939—947
[115]Yoshimura T,Yulff,i N,Moore SK,ct a1.Human monocyte chemoattractant protein-1(MCP一1):Full—length Cdna cloning, expression in mitogen—stimulated blood mononuclear leukocytes,and sequedce similarity to mouse competence gene JE.FEBS LETTERS.1989,244:487-493
[116]鲍荣辉,刘先哲.单核细胞趋化蛋白研究进展[J].综述与展.2006,35(4):58-60
[117]Ducharme L A ct al. Eur J lmmunol,1992; 22: 2603-2607
[118]Proost P,Wuyts A,Van Damme J.Human monocyte chemotactic protein-2 and-3: structural and functional comparison with MCP-1.J of Leukocyte Biology,1996,59:67-75
[119]Uchiumi,T.,M.Kikuchi,andK.Ogata,Cross-linking study on Protein neighborhoods at the subunit interface of rat liver ribosomes with2- iminothiolane.J Biol Chem,1986.261(21):p. 9663-7.
[120]Westermann,P.and O.Nygard,The spatial arrangement of thecomplex between eukaryotic initiation faetor eIF-3 and 40s ribosomal subunit. Cross-linking between factor and ribosomal proteins. Biochim BioPhys Aeta,1983.741(l):P.103-8.
[121]Fisher,E.M.,et al.,Homologous ribosomal protein genes on the Human X and Y chromosomes: escape from X inactivation and Possible implications for Tumer syndrome.Cell,1990.63(6):P. 1205-18.
[122]Synetos,D.,M.D.Dabeva,and J.R.Warner,The yeast ribosomal proteinS7 and its genes. J Biol Chem,1992.267(5):p.3008-13.
[123]Bochmann MF, KopfM, Mansland BJ, et a.l Chemokines: more than just road signs[J]. NatRev Immuno,l2006,6(2):159-164.
[124]Moepps B,Frodl R,Rodewald H,et al. Two murine homologues of the human chemokine receptor CXCR4 mediating stromal cell-derived factor 1 alpha activation of Gi2 are differentially expressed in vivo[J],Eur J Immuno1,1997,27;2102-2112.